Quantcast

Latest Beta blockers Stories

2009-02-25 08:00:00

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle...

2009-01-27 09:48:34

Multi-institutional study supports controversial theory, reveals genetic key Just when the Food and Drug Administration is reconsidering the use of stimulants to treat asthma, a new research study offers further evidence to support a University of Houston professor's theory that an opposite approach to asthma treatment may be in order. Richard A. Bond, professor of pharmacology at the University of Houston College of Pharmacy (UHCOP), has been investigating whether beta-2 adrenoreceptor...

2008-10-30 03:00:27

Hi-Tech Pharmacal, a specialty pharmaceutical company, has announced that the FDA granted final approval to the company's abbreviated new drug application for dorzolamide ophthalmic solution, 2%. Hi-Tech's dorzolamide ophthalmic solution is the generic for Merck's Trusopt ophthalmic solution 2%, indicated for elevated intraocular pressure in patients with ocular hypertension or open-angel glaucoma. Hi-Tech said that it plans to launch generic dorzolamide ophthalmic solution 2% immediately.

2008-09-15 12:00:35

Othera Pharmaceuticals, Inc., today announced that it has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma. The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension or open-angle glaucoma. Subjects will be randomized to one of 0.75%...

2008-08-24 22:57:20

By Rupali Mukherjee NEW DELHI: If you are hypertensive and have been prescribed one of the widely used class of medicines called beta blockers-drugs like atenolol, inderal and metaprolol- you could be running an unacceptable risk of diabetes. Recent research in the UK indicates that these drugs could increase blood sugar in patients suffering from diabetes, and in some cases led to onset of the disease among patients of high blood pressure. The study, carried out at National Heart and...

2008-08-01 12:01:08

BROOMFIELD, Colo., Aug. 1 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed James Carr, PharmD, as vice president of marketing. In this newly created position, Mr. Carr will define and execute marketing programs to support the company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and...

2008-08-01 06:00:46

Othera Pharmaceuticals has submitted an investigational new drug application to the FDA for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase I-II safety and efficacy trial is planned for completion by the end of 2008. This study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled, Phase I-II evaluation of the safety and efficacy of OT-730 ophthalmic solution in reducing the intraocular pressure in subjects with ocular...

2008-07-30 09:01:27

Othera Pharmaceuticals, Inc., announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase 1-2 safety and efficacy trial is planned for completion by the end of 2008. OT-730 is a novel, internally developed next generation topical beta-blocker designed to lower intra-ocular pressure (IOP), the leading risk factor for developing...

2008-03-25 15:07:02

Beta-blockers heal the heart via the brain when administered during heart failure, according to a new study by UCL (University College London). Up to now, it was thought that beta-blockers work directly on the heart, but the new study shows that the drugs may also act via the brain, suggesting that future therapies to treat cardiovascular disease could be targeting the central nervous system.Heart failure patients are routinely given beta-blockers, although doctors do not know exactly how...

2006-07-03 10:22:32

NEW YORK (Reuters Health) - Patients hospitalized for heart failure (HF) appear to have better outcomes if they are treated with beta-blockers prior to, during, and after the hospitalization, investigators report. HF is the progressive inability of the heart to pump enough blood to support vital organs and often leads to a buildup of fluid, causing swollen legs and arms, fatigue and eventually excess fluid in the lungs and severe life-threatening shortness of breath. Standard...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related